Dr Seth Ettenberg | Chief Scientific Officer
Unum Therapeutics Inc.

Dr Seth Ettenberg, Chief Scientific Officer, Unum Therapeutics Inc.

Seth Ettenberg is the Chief Scientific Officer at Unum Therapeutics. Unum is discovering and developing new cellular immunotherapies for cancer using its proprietary Antibody-Coupled T-cell Receptor (ACTR) technology. Seth is responsible for the company’s overall scientific direction and strategy, building and managing the research team, interacting with the external research environment, and helping to bring the promise of Unum’s new technology to patients in need.  He has a strong track record of immuno-oncology experience, having taken multiple biologics programs through clinical development during his career. 
Prior to Unum, Seth served as the Head of Novartis Oncology Biotherapeutics, Cambridge site. In this role, Seth led projects in all stages of development from target identification and validation through Phase 2 clinical trials. While at Novartis Seth had a demonstrated track record of invention and development with a variety of therapeutic modalities including naked antibodies, antibody drug conjugates, and novel therapeutic scaffolds. In addition, Seth was responsible for building and leading the Novartis Cell and Gene Therapy research team in collaboration with the University of Pennsylvania to develop chimeric antigen receptor T-cell therapeutics.
Prior to Novartis, Seth was a senior research scientist at CuraGen Corporation where he was responsible for the discovery and characterization of novel oncology targets and antibodies.  Before moving to industry, Seth received his formal scientific training studying the underlying mechanisms of tumor formation and receptor tyrosine kinase regulation while in the Genetics Branch of the National Cancer Institute.


WIC 2017 Day 2, Wednesday 1st November 2017 @ 11:25

Antibody Coupled T-cell Receptor (ACTR): a universal approach to cell therapy for cancer

  • T-cells expressing a chimeric receptor comprising the ectodomain of CD16 together with costimulatory and TCR signalling domains exert powerful cytotoxicity against tumor cells when combined with tumor-targeting monoclonal antibodies.
  • By separating tumor cell targeting (via the antibody) from tumor cell killing (via the engineered T-cell), ACTR therapy can be precisely controlled — potentially enhancing its safety and efficacy relative to alternative cell-based approaches.  
  • Unum is leveraging a wide range of existing antibodies to build a broad pipeline of novel T-cell + antibody combination therapies.

back to speakers